<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

On Demand Webinar

Tumor Organoids: A Paradigm Shift in Oncology Drug Discovery

Tumor Organoids: A Paradigm Shift in Oncology Drug Discovery

More clinically relevant models are urgently needed for preclinical oncology drug development. This webcast demonstrates how tumor organoids can better predict patient response, improve the success rate of new anticancer agents, and overcome high oncology drug attrition rates.

The speakers describe HUB Organoid™ features that preserve the genetic and phenotypic characteristics of the original tumor, providing a unique in vitro system for screening the efficacy of oncological drugs and enabling improved cancer drug candidates to enter the clinic.

Watch This Webinar to Learn:

  • The features of HUB Organoids
  • Why HUB Organoids are considered to be superior 3D in vitro systems
  • How to apply HUB Organoids to oncology drug development

Who Should Watch:

  • Drug developers interested in understanding the benefit of tumor organoids compared to standard 3D systems
  • Decision makers from biotech and pharmaceutical companies who are looking to enhance the translatability of their early stage drug development programs
  • Researchers interested in learning about HUB tumor organoids and their predictive power

Watch Now!


About The Presenters:

Dr. Henry LiHenry QX Li, PhD leads Crown Bioscience's Global Scientific Research and Innovation Division, focused on accelerating the creation of new, innovative products and services for discovery and translational sciences. Prior to this, Dr. Li successfully led and expanded Crown Bioscience’s patient-derived xenograft (PDX) based Translational Oncology platform (2011-2016), and led the Biomarker and Diagnostic Technologies Division developing novel proprietary translational technologies for precise cancer diagnosis, predictive biomarker discovery, immuno-oncology biomarker detection and quantification, as well as rare cell identification and characterization (2016-2018). Before joining Crown Bioscience, Dr. Li has over 20 years of biopharmaceutical, as well as academic R&D, experience in cancer and viral infection, including leadership roles as R&D Director/Senior Director in several US-based biotech companies. Dr. Li currently holds visiting Professor position at Peking University-State Key Laboratory. Dr. Li earned his Ph.D. in Molecular Biology/Biochemistry from the University of California (Irvine) and completed his postdoctoral training at UCLA School of Medicine. He has published more than 60 manuscripts and edited 3 books in the biopharmaceutical areas. He is also on the editorial board of Current Signal Transduction Therapy.

Dr. Sylvia F BojSylvia F Boj received her PhD in 2006 at the University of Barcelona, Spain for her work at IDIBAPS on functional genetic analysis for deciphering the transcriptional role of MODY genes in pancreatic beta cells. With a long term EMBO fellowship, she subsequently joined the Hubrecht Institute (Utrecht, the Netherlands) as a postdoctoral fellow. In the laboratory of Prof. Hans Clevers she first studied the role of TCF7L2 regulating metabolism. Then, she established an in vitro organoid model for human pancreatic cancers. In 2014, she moved to Hubrecht Organoid Technology (Utrecht, the Netherlands) as a group leader for Cystic Fibrosis and Cancer programs. In 2016, she was appointed as Scientific Director of the HUB, with the ultimate goal of transferring scientific advances of the Organoid Technology to the development of new drugs, by interacting with pharmaceutical companies, and developing clinical trials to validate the predictive value of the Organoids for the response of patients to certain treatments.



Download Now

Your privacy is important to us.
We'll never share your information.